Valuation: Inotiv, Inc.

Market Cap 387K 332K 309K 284K 533K 37.05M 544K 3.67M 1.43M 18.57M 1.45M 1.42M 61.48M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 375M 350M 321M 603M 41.9B 615M 4.15B 1.62B 21B 1.64B 1.61B 69.53B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
3 months-95.75%
6 months-96.07%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.89
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap.
19/7/26 Others

Chief Executive Officer

-1,361,215 3.9017%
19/7/26 Others

Director

-729,626 2.0913%
19/7/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.34%-99.67% 387K
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.36%+4.82%+485.55%+608.86% 46.01B
-2.04%+3.69%+19.34%+88.23% 42.85B
+2.72%+6.02%+33.33%+19.45% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.72%+5.27%+31.55%+149.06% 16.98B
-1.85%+3.48% - - 17.05B
+3.06%+4.63%+7.40%+35.00% 14.3B
+0.50%+3.62%+82.64%+45.06% 13.84B
Average -2.25%-2.03%+64.77%+102.01% 27.46B
Weighted average by Cap. +0.29%+2.37%+105.33%+151.44%

Financials

2024 2025
Net sales 491M 420M 392M 360M 676M 46.96B 689M 4.65B 1.81B 23.53B 1.84B 1.8B 77.91B 513M 439M 410M 376M 707M 49.09B 721M 4.86B 1.9B 24.6B 1.93B 1.88B 81.45B
Net income -108M -92.85M -86.63M -79.49M -149M -10.38B -152M -1.03B -401M -5.2B -407M -398M -17.22B -68.62M -58.76M -54.82M -50.3M -94.52M -6.57B -96.38M -650M -254M -3.29B -258M -252M -10.89B
Net Debt 424M 363M 338M 311M 584M 40.54B 595M 4.02B 1.57B 20.32B 1.59B 1.56B 67.26B 438M 375M 350M 321M 603M 41.87B 615M 4.15B 1.62B 20.98B 1.64B 1.61B 69.46B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTV Stock